

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

7 April 2026

Date of AGM and Closing Date for Director Nomination

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), is dedicated to improving healthcare outcomes through early and more accurate detection of cancers utilising its proprietary MagSense® imaging technology, gives notice in accordance with ASX Listing Rule 3.13.1 that its 2026 Annual General Meeting (AGM) is scheduled to be held on Tuesday, 26 May 2026.

Imagion also advises that, in accordance with Rule 15.4 of its Constitution, the closing date for the receipt of nomination from persons wishing to be considered for election as a Director of the Company at the 2026 AGM is 5pm AEST on Tuesday, 14 April 2026. Valid nominations must be received at the Company's registered office in Melbourne, Victoria, no later than that time and date.

Imagion's Notice of Meeting and Proxy Form for the 2026 AGM will be released to the ASX and communicated to Shareholders in due course in accordance with statutory timeframes.

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Imagion Biosystems Limited.

Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via *Investor Hub*. Register at investor.imagionbiosystems.com.

About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com.

Executive Chairman Contact Details

Bob Proulx
investor@imagionbio.com
AU: +61 3 9692 7222

Media Enquiries & Investor Relations:

Erich Boileau, Boileau & Co.
imagionbio@boileau.co
US : +1 (616) 786-4461

